Assuming regulatory approval, what role do you foresee for varegacestat (RINGSIDE) in the management of progressive desmoid tumors, particularly in relation to existing systemic treatment options?

Once-daily dosing is certainly more attractive from the patient's perspective. Apart from that, I do not foresee many differences in the impact on how we manage desmoid tumors. Since this was also a placebo-controlled trial, there is no way to judge it against nirogacestat.

Acknowledging the limitations of cross-trial comparisons, hard to overlook the possibility that varegacestat is a more potent GSI reflected in higher RR, better HR, and the higher median decrease in tumor volume. The once-a-day dosing is also likely to be an added attraction. Clearly, the dose adjus...